<DOC>
	<DOCNO>NCT00084214</DOCNO>
	<brief_summary>This study design assess efficacy weekly treatment regimen STA-4783 paclitaxel comparison paclitaxel alone tumor response metastatic melanoma patient .</brief_summary>
	<brief_title>STA-4783/Paclitaxel Paclitaxel Alone Melanoma</brief_title>
	<detailed_description>STA-4783 taxane potentiator , enhance effect antitumor response paclitaxel . In attempt improve efficacy , paclitaxel sometimes used combination anticancer agent . When paclitaxel combine anticancer agent , although response rate usually increase , side effect usually increase well . There urgent need agent enhance antitumor effect paclitaxel without increase undesirable side effect .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>M F 18 old histologically confirm metastatic ( Stage IV ) melanoma cutaneous origin ECOG performance status great equal 2 Measurable disease per RECIST criterion Received 1 regimen prior chemotherapy ( unlimited immunotherapy regimen allow ) At least 4 week pass since last chemotherapy immunotherapy At least 2 week pass since last radiotherapy . Life expectancy great 12 week Clinical lab value within protocol parameter Female patient pregnant lactate Female patient childbearing potential use willing use effective contraception Presence second malignancy nonmelanoma skin cancer Presence clinically significant uncontrolled infection Presence clinically significant arrythmias Presence serious concurrent illness condition permit adequate followup compliance protocol History severe hypersensitivity reaction taxanes Use investigational agent within 4 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>metastatic</keyword>
	<keyword>increase antitumor effect</keyword>
</DOC>